Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 282

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 7
Chunk 282
---
%25.3 %Total$224 $436 $666 (48.7)%(34.6)%(48.1)%(34.2)%Other Eye CareUnited States$472 $433 $399 8.9 %9.0 %8.9 %9.0 %International375 370 348 1.5 %6.1 %6.1 %8.7 %Total$847 $803 $747 5.5 %7.6 %7.6 %8.8 %Other Key ProductsMavyretUnited States$595 $659 $755 (9.7)%(12.7)%(9.7)%(12.7)%International716 771 786 (7.2)%(1.9)%(4.5)%1.0 %Total$1,311 $1,430 $1,541 (8.3)%(7.2)%(6.9)%(5.7)%CreonUnited States$1,383 $1,268 $1,278 9.1 %(0.8)%9.1 %(0.8)%Linzess/ConstellaUnited States$916 $1,073 $1,003 (14.6)%7.1 %(14.6)%7.1 %International38 35 32 7.5 %8.8 %7.2 %9.7 %Total$954 $1,108 $1,035 (13.9)%7.1 %(13.9)%7.1 %All other$3,032 $3,035 $4,137 — %(26.7)%1.4 %(25.7)%Total net revenues$56,334 $54,318 $58,054 3.7 %(6.4)%4.6 %(5.9)%

n/m – Not meaningful

(a)Net revenues include ImmunoGen product revenues after the acquisition closing date of February 12, 2024.

The following discussion and analysis of AbbVie's net revenues by product is presented on a constant currency basis.

Global Humira sales decreased 37% in 2024. In the United States, Humira sales decreased 41% in